Cargando…

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study

Clostridioides difficile infection (CDI) has significant implications for healthcare economics. Although clinical trials have compared fidaxomicin (FDX) and vancomycin, comparisons of FDX and oral metronidazole (MNZ) are limited. Therefore, we compared the therapeutic effects of FDX and oral MNZ. Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Nobuaki, Hirai, Jun, Ohashi, Wataru, Asai, Nobuhiro, Shibata, Yuichi, Mikamo, Hiroshige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451525/ https://www.ncbi.nlm.nih.gov/pubmed/37627743 http://dx.doi.org/10.3390/antibiotics12081323

Ejemplares similares

Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review
por: Mori, Nobuaki, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
por: Hirai, Jun, et al.
Publicado: (2023)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

A Retrospective Study to Compare the Incidence of Hyponatremia after Administration between Linezolid and Tedizolid
por: Shibata, Yuichi, et al.
Publicado: (2023)

Intra-Abdominal Abscess and Bacteremia Due to Stenotrophomonas maltophilia After Total Gastrectomy: A Case Report and Literature Review
por: Hirai, Jun, et al.
Publicado: (2023)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Necrotizing pneumonia due to Pseudomonas aeruginosa secondary to severe COVID‐19 pneumonia
por: Hirai, Jun, et al.
Publicado: (2023)

A Case of Severe Pneumocystis Pneumonia in an HIV-Negative Patient Successfully Treated with Oral Atovaquone
por: Hirai, Jun, et al.
Publicado: (2023)

Silver-colored colonies of Staphylococcus argenteus
por: Hirai, Jun, et al.
Publicado: (2023)

Plasmid-mediated metronidazole resistance in Clostridioides difficile
por: Boekhoud, Ilse M., et al.
Publicado: (2020)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

A Gap of Patients with Infective Endocarditis between Clinical Trials and the Real World
por: Asai, Nobuhiro, et al.
Publicado: (2023)

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France
por: Guery, Benoit, et al.
Publicado: (2021)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation
por: Hagihara, Mao, et al.
Publicado: (2021)

692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States
por: Lee, Yuman, et al.
Publicado: (2023)

474. Real-World Experience of the Comparative Effectiveness and Safety of Remdesivir and Combination Therapy (Remdesivir and Monoclonal Antibodies) in Immunosuppressed Patients with Mild to Moderate COVID-19: A Retrospective Single-center Study in a Community Setting
por: Hirai, Jun, et al.
Publicado: (2023)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates
por: Smits, Wiep Klaas, et al.
Publicado: (2022)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis
por: Brauer, Madita, et al.
Publicado: (2022)

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Comparative Effectiveness of Ampicillin/Sulbactam versus Cefazolin as Targeted Therapy for Bacteremia Caused by Beta-Lactamase-Producing Methicillin-Sensitive Staphylococcus aureus: A Single-Center Retrospective Study
por: Hirai, Jun, et al.
Publicado: (2022)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Complicated pyelonephritis caused by Proteus alimentorum in a woman with peritoneal cancer: a case report
por: Mori, Nobuaki, et al.
Publicado: (2023)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

392. Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States
por: Basir, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_trf0v2hbitmfh0bju92svs8jfj